30,000 Shares in OptimizeRx Co. (NASDAQ:OPRX) Acquired by Delta Investment Management LLC

Delta Investment Management LLC acquired a new stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 30,000 shares of the company's stock, valued at approximately $146,000. Delta Investment Management LLC owned 0.16% of OptimizeRx at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Wells Fargo & Company MN lifted its holdings in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after acquiring an additional 2,797 shares during the period. Barclays PLC increased its holdings in shares of OptimizeRx by 13.5% during the 4th quarter. Barclays PLC now owns 30,574 shares of the company's stock valued at $148,000 after purchasing an additional 3,640 shares in the last quarter. Perkins Capital Management Inc. lifted its stake in shares of OptimizeRx by 4.4% in the 4th quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company's stock valued at $514,000 after purchasing an additional 4,450 shares during the period. Geode Capital Management LLC boosted its holdings in OptimizeRx by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock worth $1,948,000 after buying an additional 4,821 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the fourth quarter valued at $25,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at OptimizeRx

In other news, Director James Paul Lang purchased 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The shares were purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This represents a 472.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.60% of the company's stock.

Analyst Upgrades and Downgrades

OPRX has been the topic of several recent analyst reports. B. Riley reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Stifel Nicolaus boosted their price target on shares of OptimizeRx from $8.00 to $12.50 and gave the stock a "buy" rating in a report on Tuesday, May 13th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, JMP Securities lifted their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $10.38.

OptimizeRx Price Performance

OPRX stock traded down $0.44 during mid-day trading on Monday, reaching $11.65. The company's stock had a trading volume of 250,250 shares, compared to its average volume of 279,372. The stock has a market cap of $215.47 million, a PE ratio of -8.76 and a beta of 1.28. The company's 50 day moving average is $9.16 and its two-hundred day moving average is $6.71. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $13.00. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.19. The firm had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. Equities research analysts expect that OptimizeRx Co. will post -0.33 EPS for the current year.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.